Marlinz Pharma announced the formal launch of its 6000MG CBG/CBD Transdermal Cream on February 1, 2024. The product features a patented transdermal delivery vehicle that carries a combination of 3000MG of CBG (cannabigerol) and 3000MG of CBD (cannabidiol) deep into soft tissues and the surfaces of bone where most common sources of pain and inflammation develop. It is non-addictive and completely THC-free. There are many National Institute of Health studies on the effects of CBG and CBG on many of the most common conditions physicians treat today. The new transdermal cream represents yet another first-of-its-kind proprietary topical drug or product Marlinz has brought to market since its inception in 2017.
Marlinz Pharma Launches Revolutionary Transdermal CBG/CBD Cream
